Document Detail


Blood pressure effects of COX-2 inhibitors.
MedLine Citation:
PMID:  16785828     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There has been significant recent interest in the cardiovascular effects of cyclooxygenase 2 (COX-2) selective inhibitors. Whereas much attention has been focused on the putative prothrombotic effect of these agents, their cardiorenal and blood pressure elevating actions may be of equal if not greater importance to cardiovascular risk. COX-2 is widely expressed throughout the kidney, and inhibition of this enzyme is contributory to reduced glomerular filtration, salt and water retention, and blood pressure elevation. The key issues in relation to COX-2 inhibitors and blood pressure are whether these blood pressure-elevating effects are similar to or differ from nonselective nonsteroid anti-inflammatory drugs, whether differences exist among COX-2 inhibitors in regard to blood pressure regulation, and if so, possible mechanisms underlying blood pressure differences between COX-2 inhibitors. With regard to the last issue, possible mechanisms include greater COX-2 selectivity of certain agents such as rofecoxib, the differing half-life of these agents, the carbonic anhydrase activity of celecoxib (which may offset renal-induced salt and water retention), and possible aldosterone modulation by rofecoxib. Finally, and perhaps most important, the issue arises as to whether blood pressure elevation may contribute in whole or in part to the increase in cardiovascular events observed with these agents in some but not all studies. Ultimately, adequately powered, prospective randomized clinical trials assessing relevant cardiovascular endpoints are required to address many of these outstanding questions. Such studies have recently been announced and will commence soon.
Authors:
Henry Krum; Tai-Juan Aw; Danny Liew; Steven Haas
Related Documents :
17942408 - Vascular hypertrophy and hypertension caused by transgenic overexpression of profilin 1.
1736928 - A gender difference in the association between salt sensitivity and family history of h...
11244008 - Adverse cardiac effects of salt with fludrocortisone in hypertension.
20131938 - End-organ damage in hypertensive transgenic ren-2 rats: influence of early and late end...
6625638 - Expiration induced femoral flow in neonatal coarctation of aorta.
8022218 - Coupling of the left ventricular and arterial system.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  47 Suppl 1     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2006  
Date Detail:
Created Date:  2006-06-20     Completed Date:  2006-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S43-8     Citation Subset:  IM    
Affiliation:
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. henry.krum@med.monash.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Pressure / drug effects*
Coronary Vessels / drug effects
Cyclooxygenase 2 Inhibitors / pharmacology*
Heart / drug effects
Humans
Kidney / drug effects
Chemical
Reg. No./Substance:
0/Cyclooxygenase 2 Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  COX-2 and the kidney.
Next Document:  Why and how to use NSAIDs in osteoarthritis.